Rose SR, Carlsson M, Grimberg A, et al. - Researchers conducted the study for identifying differences in growth response to GH therapy (GHT) according to the type/location of radiation therapy (RT). KIGS (Pfizer International Growth Database) has been searched for cancer survivors on GHT for ≥ 5y. Patient data, grouped by type of tumor, have been analyzed for therapy (surgery, chemotherapy, RT—focal CNS, cranial, craniospinal, or total body RT [TBI] as part of bone marrow transplantation), gender, peak stimulated GH, age at GHT start, and duration from RT to GHT start. Of 1,149 GH deficiency survivors on GHT for ≥ 5y (male 733; median age 8.4y; GH peak 2.8 ng/mL), 431 had craniopharyngioma (251, cranial RT), 224 medulloblastoma (craniospinal RT), 134 leukemia (72, TBI), and 360 other tumors. TBI for leukemia had a significant effect on growth response to GHT. Survivors of medulloblastoma had an intermediate GHT response, whereas craniopharyngioma cranial RT did not alter GHT response. Both craniospinal and epiphyseal irradiation have a negative effect on growth response to GH therapy compared with cranial RT alone or no radiation therapy.